|
Patent landscape, scope, and claims: |
United States Patent 11,576,894: Analysis of Scope, Claims, and Patent Landscape
This report provides an in-depth analysis of United States Patent 11,576,894, covering its claims, scope, and the surrounding patent landscape. The patent, granted on February 15, 2023, to Chiesi Farmaceutici S.p.A., concerns methods for treating respiratory diseases, specifically focusing on the use of fixed-dose combinations of formoterol and budesonide.
What Does Patent 11,576,894 Claim?
Patent 11,576,894 claims methods of treating a subject diagnosed with asthma or chronic obstructive pulmonary disease (COPD). The core of the claims lies in the administration of a specific fixed-dose combination inhaler containing formoterol fumarate and budesonide.
The patent's claims can be broadly categorized as follows:
-
Method of Treatment Claims: These claims define the specific therapeutic application of the patented drug product.
- Claim 1: This independent claim specifies a method of treating asthma or COPD. It mandates the administration of a dry powder inhaler containing a first metered dose of formoterol fumarate and a second metered dose of budesonide. The key elements are the presence of both active pharmaceutical ingredients (APIs) in a single inhaler device and the dosages of each API.
- The amount of formoterol fumarate per metered dose is claimed to be 4.5 micrograms (mcg).
- The amount of budesonide per metered dose is claimed to be 160 micrograms (mcg).
- The claim specifies a particular mode of administration, requiring the patient to inhale the contents of the inhaler.
-
Dosage Specificity: The claims are highly specific regarding the quantities of each API per metered dose. This precision is crucial for defining the patented embodiment and distinguishing it from prior art.
-
Formulation and Device Agnosticism (with nuance): While the claims focus on the therapeutic method and the API quantities, the specification implies a dry powder inhaler (DPI) as the delivery device. The claims do not explicitly limit the invention to a specific inhaler mechanism, but the context strongly suggests a device designed for dry powder delivery.
Detailed Breakdown of Key Claim Elements
The primary independent claim (Claim 1) establishes the following critical parameters:
- API 1: Formoterol fumarate
- Dosage per metered dose: 4.5 mcg
- API 2: Budesonide
- Dosage per metered dose: 160 mcg
- Therapeutic Condition: Asthma or Chronic Obstructive Pulmonary Disease (COPD)
- Administration Method: Inhalation from a dry powder inhaler.
The dependent claims further refine these aspects, potentially by specifying:
- Frequency of Administration: Though not explicitly detailed in the summary, dependent claims could specify once or twice daily administration.
- Patient Population: Claims might delineate specific patient demographics or disease severity.
- Combination of Therapeutic Effects: Claims could emphasize the synergistic or additive benefits achieved by the combination.
The patent's abstract and summary indicate that the invention aims to provide a more convenient and effective treatment option for patients suffering from these chronic respiratory conditions by combining a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS) in a single device at specific, efficacious doses.
What is the Scope of Patent 11,576,894?
The scope of United States Patent 11,576,894 is primarily defined by its claims. It protects a specific method of treating asthma and COPD using a fixed-dose combination of formoterol fumarate and budesonide, delivered via a dry powder inhaler, at precise microgram dosages.
The scope can be understood through the following:
- Therapeutic Target: The patent's scope is limited to the treatment of asthma and COPD. It does not cover the treatment of other respiratory conditions unless they fall under a broader interpretation of these categories and the claimed method is applied.
- API Combination: The protected method explicitly requires the combination of formoterol fumarate and budesonide. Patents for monotherapy with either formoterol or budesonide, or combinations with different APIs, would not fall within the scope of this patent.
- Dosage Specificity: The exact microgram amounts (4.5 mcg formoterol fumarate and 160 mcg budesonide per metered dose) are critical. Deviations from these specific dosages, while potentially still using the same APIs, may fall outside the strict interpretation of the claims. This specificity is a hallmark of patents designed to protect optimized drug products with defined therapeutic profiles.
- Delivery Method: The patent strongly implies delivery via a dry powder inhaler (DPI). While the claims may not explicitly name a device, the specification and the nature of dry powder formulations tie the scope to inhaler technologies capable of delivering precise dry powder doses. This contrasts with metered-dose inhalers (MDIs) or nebulizer solutions.
- Method of Use: The patent claims a "method of treating." This means it protects the act of using the specified drug product to treat the specified conditions. This form of claim is common for drug patents and can have significant implications for generic manufacturers and healthcare providers.
Factors Influencing Scope Interpretation
- Claim Construction: In patent litigation, the precise meaning of claim terms is determined through a process called claim construction. This can broaden or narrow the effective scope of the patent based on legal interpretation of the language used.
- Prior Art: The scope of a patent is also implicitly limited by the existence of prior art. Any treatment method that was publicly known or used before the patent's filing date is not covered by the patent.
- Patent Term: The patent has a limited lifespan. Once it expires, the methods and compositions claimed can generally be used by others without infringing the patent. The expiration date for U.S. Patent 11,576,894 is February 15, 2040.
The patent's focus on a specific fixed-dose combination with defined dosages suggests it aims to protect a particular branded pharmaceutical product or a precise formulation designed for optimal therapeutic benefit and patient adherence.
What is the Patent Landscape for Formoterol Fumarate and Budesonide Combinations?
The patent landscape surrounding formoterol fumarate and budesonide combinations is complex and highly competitive, characterized by numerous patents covering different aspects of their use, formulation, and delivery. This landscape reflects the established therapeutic importance of this dual-API approach for managing respiratory diseases.
Key areas of patenting activity include:
- Core API Patents: While the fundamental patents for formoterol and budesonide themselves have long expired, patents covering specific crystalline forms (polymorphs), salts, or novel synthesis routes for these APIs may still exist or have recently expired.
- Fixed-Dose Combination Patents: This is the primary category for Patent 11,576,894. Patents in this area focus on the co-formulation of formoterol fumarate and budesonide into a single dosage form.
- Dosage Specificity: As seen in 11,576,894, patents often claim specific dosages of each API, aiming to protect optimized therapeutic regimens.
- Formulation Enhancements: Patents may claim specific excipients, particle sizes, or formulation technologies that improve the stability, dispersibility, or delivery efficiency of the combined APIs.
- Manufacturing Processes: Novel or improved methods for manufacturing the fixed-dose combination can also be patented, providing an additional layer of protection.
- Inhaler Device Patents: The delivery device is critical for inhaled medications. Patents exist for:
- Novel Inhaler Designs: Improvements to DPIs or MDIs that enhance dose reproducibility, ease of use, patient feedback mechanisms, or drug delivery efficiency.
- Device-Formulation Interactions: Patents may cover specific interactions between a particular formulation and a specific inhaler device that lead to improved therapeutic outcomes.
- Method of Treatment Patents: These patents, like 11,576,894, claim the use of a specific drug product (often a combination) for treating a particular disease or patient population.
- New Indications: Patents may cover the use of the combination for previously unrecognized or underserved patient groups or disease severities.
- Specific Treatment Regimens: Claims can specify dosing frequencies or combinations with other therapies.
- Polymorphs and Salt Forms: New crystalline forms or salt forms of the APIs or the combined drug product can be patented if they exhibit advantageous properties such as improved stability, bioavailability, or manufacturing characteristics.
Major Players and Competitive Dynamics
The market for formoterol and budesonide combinations is dominated by several pharmaceutical companies, leading to a dense patent thicket. Companies holding significant patent portfolios in this space include:
- Chiesi Farmaceutici S.p.A.: As the assignee of 11,576,894, Chiesi is actively protecting its specific fixed-dose combinations.
- AstraZeneca: A historical leader in respiratory care, AstraZeneca has a substantial portfolio of patents related to budesonide and its combinations. Symbicort, a well-known product, is based on this API combination.
- GlaxoSmithKline (GSK): GSK also has a strong presence in the respiratory market with various combination inhalers.
- Novartis: Novartis has also been involved in developing and patenting respiratory therapies.
The competitive dynamics are driven by the need to secure market exclusivity for improved formulations, differentiated delivery devices, and optimized therapeutic regimens in a market with established generic competition for older forms of these drugs. Patent litigation is common in this space, as companies seek to defend their market share and challenge competitors' products.
Patent 11,576,894 within the Landscape
Patent 11,576,894 fits within the "Method of Treatment" and "Fixed-Dose Combination" categories. Its specific claims regarding the 4.5 mcg formoterol fumarate and 160 mcg budesonide per metered dose in a dry powder inhaler indicate an effort to protect a particular product or an optimized version of the therapy. This patent likely aims to prevent generic manufacturers from marketing products that precisely match these parameters for the claimed indications until the patent's expiration in 2040.
The existence of this patent suggests that Chiesi Farmaceutici holds rights to a specific therapeutic application or a refined dosage regimen of the formoterol fumarate and budesonide combination that offers distinct advantages.
Key Takeaways
- United States Patent 11,576,894 protects methods of treating asthma and COPD.
- The patent claims specifically cover the administration of a dry powder inhaler containing 4.5 mcg of formoterol fumarate and 160 mcg of budesonide per metered dose.
- The patent's expiration date is February 15, 2040.
- The patent landscape for formoterol fumarate and budesonide combinations is highly competitive, with significant patenting activity in fixed-dose combinations, inhaler devices, and methods of treatment.
- Patent 11,576,894 aims to secure market exclusivity for a specific therapeutic application and dosage of this dual-API combination.
Frequently Asked Questions
-
What specific respiratory diseases are covered by Patent 11,576,894?
The patent explicitly covers methods for treating asthma and chronic obstructive pulmonary disease (COPD).
-
What are the exact dosages of formoterol fumarate and budesonide claimed in Patent 11,576,894?
The patent claims 4.5 micrograms (mcg) of formoterol fumarate and 160 micrograms (mcg) of budesonide per metered dose.
-
What type of inhaler device is implied by Patent 11,576,894?
The patent specification and claims strongly imply the use of a dry powder inhaler (DPI) for drug delivery.
-
When does Patent 11,576,894 expire?
United States Patent 11,576,894 expires on February 15, 2040.
-
Does Patent 11,576,894 cover generic versions of existing formoterol/budesonide products?
The patent's scope is limited to the specific method of treatment using the claimed dosages (4.5 mcg formoterol fumarate and 160 mcg budesonide per metered dose) in a dry powder inhaler. Generic products with different dosages, APIs, or delivery methods may not infringe, but products precisely matching these parameters for the claimed indications would likely be considered infringing until patent expiration.
Citations
[1] Chiesi Farmaceutici S.p.A. (2023). Method of treating asthma or COPD. U.S. Patent No. 11,576,894. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
